Home›Alprazolam C-Iv

Alprazolam C-Iv

Also known as: Ceprotin

Benzodiazepine

Route: Oral

Check Alprazolam C-Iv Interactions →
28 interactions on record⛔ Black Box Warning

Alprazolam C-Iv has 28 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 17 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Alprazolam C-Iv should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
28
Contraindicated
4
Major
17
Moderate
7

Contraindicated (4)

  • Alprazolam C-Iv + Clarithromycin— Concomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting …
  • Alprazolam C-Iv + Itraconazole— Concomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting …
  • Alprazolam C-Iv + Ketoconazole— Concomitant use with strong CYP3A inhibitor is contraindicated due to profound effect on alprazolam clearance resulting …
  • Alprazolam C-Iv + Ritonavir— Strong Inhibitors of CYP3A (except ritonavir) Clinical implication Concomitant use of alprazolam with strong CYP3A inhib…

Major (17)

  • Alprazolam C-Iv + Alfentanil— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Buprenorphine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Butorpenol— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Codeine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Dihydrocodeine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Fentanyl— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Hydromorphone— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Meperidine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Methadone— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Morphine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Oxycodone— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Oxymorphone— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Pentazocine— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Remifentanil— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Sufentanil— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Tapentadol— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…
  • Alprazolam C-Iv + Tramadol— Concomitant use increases risk of respiratory depression due to additive CNS effects at different receptor sites. Monito…

Moderate (7)

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations